Plasma Fibrinogen Qualification as a Drug Development Tool in Chronic Obstructive Pulmonary Disease: Perspective of the Chronic Obstructive Pulmonary Disease Biomarker Qualification Consortium
Bruce E. Miller, David M. Mannino(COPD Foundation), John Walsh, Armin Furtwaengler(Boehringer Ingelheim (Germany)), Thomas R. Martin(University of Washington), Jeffrey A. Snyder(Boehringer Ingelheim (United States)), Ubaldo J. Martin(AstraZeneca (United States)), Debora Merrill(COPD Foundation), Stephen I. Rennard(University of Nebraska at Omaha), M Lowings(GlaxoSmithKline (United Kingdom)), Nancy Kline Leidy(Health Outcomes Solutions (United States)), Ruth Tal‐Singer
Cited by 128
Related Papers
Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper
|European Respiratory Journal|2004|4.4k
Development and first validation of the COPD Assessment Test
|European Respiratory Journal|2009|3.2k
Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease
|New England Journal of Medicine|2010|3k
International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study
|The Lancet|2007|2.4k
Into the Eye of the Cytokine Storm
|Microbiology and Molecular Biology Reviews|2012|2k